Although interferon-gamma, interleukin-10, and adiponectin are key immunopathogenesis mediators of tuberculosis, their association with clinical manifestations of early stage disease is inconclusive. We determined interferon-gamma, interleukin-10, and adiponectin levels in clinically and phenotypically well-characterised non-substance using new pulmonary tuberculosis patients (n = 13) and contr...

We investigated which is the shortest fragment of the interferon gamma receptor with ligand binding capacity. A recombinant soluble interferon gamma receptor produced in Escherichia coli was subjected to controlled digestion with several proteolytic enzymes. The fragments generated were assayed by four approaches for interferon gamma binding. A 25-kDa polypeptide comprising residues 6-227 of th...

OBJECTIVE To determine the frequency and severity of leucopenia during antiviral treatment in patients with hepatitis C and the effectiveness of G-CSF (Granulocyte-Colony Stimulating Factor) in its management. STUDY DESIGN An observational study. PLACE AND DURATION OF STUDY Shafi Clinic, Rawalpindi, from July 2005 to July 2007. METHODOLOGY Patients with Polymerase Chain Reaction (PCR) pos...

BACKGROUND Type I interferons have pleiotropic effects on host cells, including inhibiting telomerase in lymphocytes and antiviral activity. We tested the hypothesis that long-term interferon treatment would result in significant reduction in average telomere length in peripheral blood T lymphocytes. METHODS/PRINCIPAL FINDINGS Using a flow cytometry-based telomere length assay on peripheral b...

Background:The premature termination of high producer clones, which will be killed due to cell proliferation and proteins production antagonism, is one of the basic drawback in recombinant proteins technology. Furtheremore, it is supposed some toxic proteins like interferon which we intended to clone and express, inhibit host cells’ proliferation. So, it is necessary to tightly control IFN-γ pr...

Background: Nowadays, the immune response to hepatitis C (HCV) treatment has become a crucial issue mostly due to the interleukin 28B (IL-28B) polymorphism effects in chronic HCV patients. The aim of this study was to detect the polymorphism of IL-28B gene (rs12979860) in HCV genotype 1 patients treated with pegylated Interferon and Ribavirin. Methods...

Methods We performed a prospective cohort study in HIV/HBV treatment-naïve coinfected patients taking care at “La Raza” National Medical Center, Mexico City. Patients were treated with Efavirenz or Lopinavir-ritonavir, each with tenofovir/emtricitabine plus pegylated interferon alfa-2b (1.5 μg/kg/week) or pegylated interferon alfa-2a (180 μg/week) during 48 weeks. HBV genetic analysis was obtai...

Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act on the viral machinery to inhibit replication. Numerous direct-acting antivirals are in development, and four have been brought to market. Simeprevir, a second-generation protease inhibitor, has been approved for HCV genotype 1 patients in combination...

The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management....

PURPOSE To identify the effect of pegylated interferon ƒ¿-2b and ribavirin treatment in the ocular fundus examination, visual acuity, and visual field. METHODS Prospective observational study was performed at the Hepatology Clinic of Sao Jose Regional Hospital and at the Vitreoretinal Department at the Sadalla Amin Ghanem Eye Hospital in patients with chronic hepatitis C before and during tre...